Waiting for JAK inhibitor safety data.

Area of Science:

• Rheumatology
• Pharmacology
• Clinical Medicine

Background:

• The US FDA issued a black box warning for Janus kinase (JAK) inhibitors used in treating inflammatory conditions.
• This warning follows the ORAL Surveillance study, comparing tofacitinib with TNF-alpha inhibitors in rheumatoid arthritis patients.
• Concerns arise as safety data for other JAK inhibitors are still pending, creating uncertainty in clinical practice.

Purpose of the Study:

• To propose a pragmatic approach for clinical decision-making regarding JAK inhibitor use.
• To guide clinicians in risk stratification for patients undergoing JAK inhibitor therapy.
• To emphasize tailoring treatment based on individual patient risk factors and preferences.

Main Methods:

• Review of the FDA's black box warning and the ORAL Surveillance study findings.
• Identification of general risk factors for venous thromboembolic events (VTE), major adverse cardiac events (MACE), and cancer.
• Development of a risk stratification framework to guide clinical decisions.

Main Results:

• Patients at highest risk for adverse events were older and had pre-existing risk factors.
• The study highlights the importance of effect modification by patient-specific risk factors.
• A proposed model involves assessing general risk factors and specific VTE/MACE risk factors.

Conclusions:

• A pragmatic, risk-stratified approach is necessary for the routine use of JAK inhibitors.
• Clinical decision-making should incorporate patient age, smoking status, and history of VTE, MACE, or cancer.
• Optimal treatment strategies require shared decision-making, balancing efficacy with individual patient risk factors and preferences.